Which country is Trametinib produced in?

Trametinib (Trametinib) was originally developed and produced by GlaxoSmithKline (GSK). In May 2013, it was approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma. It was subsequently approved for the treatment of a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer. The original drug of Trametinib is relatively expensive after it is launched on the market. Other overseas pharmaceutical companies also produce generic drugs of Trametinib, which are cheaper than the original drug.

Trametinib, as aMEK inhibitor, can selectively inhibit the activity of MEK kinase. MEK is a key component in the MAPK/ERK signaling pathway, mediating processes such as cell proliferation, differentiation, and survival by phosphorylating ERK. The function of trametinib is to block the activity of MEK kinase, thereby interfering with the normal function of this signaling pathway, thereby inhibiting the proliferation and survival of cancer cells, including melanoma, non-small cell lung cancer, etc.

The original drug of trametinib has been launched in China and has entered the scope of Class B medical insurance, but it may only be purchased by patients who meet the indications of trametinib, such as BRAF V600 mutation-positive unresectable or metastatic melanoma. Its price is around 10,000 to 20,000 yuan. The reimbursement ratio is different in different regions, and the price is also different, making it expensive. The price of the Turkish version of the original drug Trametinib listed overseas is around RMB 7,900 (the price may fluctuate due to the exchange rate). The price of the generic version of Trametinib produced by the Lao pharmaceutical factory is around RMB 2,950 (the price may fluctuate due to the exchange rate). The ingredients and efficacy of foreign generic drugs are basically the same as those of the domestic and foreign original drugs.